Submitted by admin on September 16, 2024 - 11:12am
Novartis’ breast cancer trial of Kisqali reveals 28.5% risk reduction
ESMO: Bayer hopes to expand Nubeqa's prostate cancer reach with chemo-free regimen
Biopharma prepares to pivot from China as Biosecure Act advances
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
*please scroll down for all the latest news*
